1. Home
  2. Vol 54, No 4 (2022)
  3. Santoso

Polymorphisms of SLCO1B1 Gene in Sundanese Ethnic Population of Tuberculosis Patients in Indonesia

Prayudi Santoso, Henny Juliastuti, Heda Melinda Nataprawira, Arto Yuwono Soeroto, Bachti Alisjahbana, Rovina Ruslami, Josephine Debora, Yunia Sribudiani, Ani Melani Maskoen

Abstract


Background: The blood level of rifampicin, one of the tuberculosis (TB) drugs, depends on the organic anion transporting polypeptide 1B1 (OATP1B1) in hepatocytes. This protein is encoded by the solute carrier organic anion 1B1 (SLCO1B1) gene. Its genetic variation has been reported to have an impact on clinical outcomes and drug efficacy. However, the polymorphism in the SLCO1B1 gene has not been examined in Indonesia yet. We aimed to identify the frequency of polymorphism in SLCO1B1 gene among pulmonary TB patients in Bandung, Indonesia. Methods: Cross-sectional study was conducted in West Java. 145 pulmonary TB patients who were treated with first-line drugs treatment (including rifampicin 450 mg daily) were analyzed for polymorphism in SLCO1B1 gene. Patients aged between 18–64 years old and mainly came from Sundanese ethnic group (92.4%). Genetic variants were detected using Polymerase Chain Reaction (PCR) and Sanger sequencing. Results: Polymorphism of c.463C>A(rs11045819) was not identified, while heterozygous and homozygous polymorphism of c.85-7793C>T(rs4149032) were identified in 74 (51.0%) and 56 (38.6%) patients, respectively. The minor allele frequency (MAF) of T (mutant) allele of c.85-7793C>T(rs4149032) was 64.13% (186/209), higher than in the general population, which the MAF of rs4149032 is 53.6% based on 1000 genome database. Conclusion: This study highlights the presence of different allele frequencies of polymorphisms within the population, which might affect treatment outcomes.


Keywords


c.85-7793C>T (rs4149032); c.463C>A (rs11045819); drug transporter; gene polymorphism; West Java; Indonesia

References


Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nature Reviews Disease Primers. 2016;2(1):16076. doi:10.1038/nrdp.2016.76

World Health Organization. International standards for tuberculosis care. 3rd edition. 2014.

Vernon AA. Current Standard Treatment. Antituberculosis chemotherapy. Karger Publishers; 2011. p. 61-72.

Ahmad Z, Makaya NH, Grosset J. History of drug discovery: Early evaluation studies and lessons learnt from them. Antituberculosis chemotherapy. Karger Publishers; 2011. p. 2-9.

Gumbo T. Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. Goodman & Gilman’s The pharmacological basis of therapeutics. 2011;12:1549-70.

Abulfathi AA, Decloedt EH, Svensson EM, Diacon AH, Donald P, Reuter H. Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis. Clinical Pharmacokinetics. 2019;58(9):1103-29.

Stott K, Pertinez H, Sturkenboom M, et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrobial Chem. 2018;73(9):2305-13.

Chigutsa E, Visser ME, Swart EC, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrobial Agents and Chemotherapy. 2011;55(9):4122-7.

Weiner M, Peloquin C, Burman W, et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrobial agents and chemotherapy. 2010;54(10):4192-4200.

Litjens CH, van den Heuvel JJW, Russel FG, Aarnoutse RE, Te Brake LH, Koenderink JB. Rifampicin transport by OATP1B1 variants. Antimicrobial Agents and Chemotherapy. 2020;64(10):e00955-20.

Prasad B, Evers R, Gupta A, et al. Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex. Drug Metabolism and Disposition. 2014;42(1):78-88.

Lee HH, Ho RH. Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Brit J Clin Pharmacol. 2017;83(6):1176-84.

Rattanacheeworn P, Chamnanphon M, Thongthip S, et al. SLCO1B1 and ABCG2 gene polymorphisms in a Thai population. Pharmacogenomics and Personalized Medicine. 2020;13:521.

Kwara A, Cao L, Yang H, et al. Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. Pharmacotherapy: J Human Pharmacol Drug Ther. 2014;34(3):265-71.

Dompreh A, Tang X, Zhou J, et al. Effect of genetic variation of NAT2 on isoniazid and SLCO1B1 and CES2 on rifampin pharmacokinetics in Ghanaian children with tuberculosis. Antimicrobial Agents and Chemotherapy. 2018;62(3):e02099-17.

Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacological Reviews. 2011;63(1):157-81.

Roe BA, Crabtree JS, Khan A. DNA isolation and sequencing. vol 11. Wiley-Blackwell; 1996.

World Health Organization. Global tuberculosis report 2017 (WHO/HTM/TB/2017.23). World Health Organization, Geneva, Switzerland http://apps who int/iris/bitstream/10665/191102/1/9789241565059_eng pdf. 2017;

Ruslami R, Nijland H, Aarnoutse R, et al. Evaluation of high-versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis. Antimicrobial Agents and Chemotherapy. 2006;50(2):822-3.

Ruslami R, Nijland HM, Alisjahbana B, Parwati I, van Crevel R, Aarnoutse RE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrobial Agents and Chemotherapy. 2007;51(7):2546-51.

Meyer zu Schwabedissen HE, Grube M, Kroemer HK. Pharmacogenetics of drug transporters. Pharmacogenetics and Individualized Therapy. 2012:101-48.

Giacomini KM SY. Membrane transporters and drug response. Goodman & Gilman’s the pharmacological basis of therapeutics. 2018:65–84.

Shargel L, Andrew B, Wu-Pong S. Applied biopharmaceutics & pharmacokinetics. 6th ed. Appleton & Lange Stamford; 2012.

Thomas L, Sekhar Miraj S, Surulivelrajan M, Varma M, Sanju CS, Rao M. Influence of single nucleotide polymorphisms on rifampin pharmacokinetics in tuberculosis patients. Antibiotics. 2020;9(6):307.

McIlleron H, Abdel-Rahman S, Dave JA, Blockman M, Owen A. Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research. J Infect Dis. 2015;211(suppl3):S115-S125.

Ramesh K, Hemanth Kumar A, Kannan T, et al. SLCO1B1 gene polymorphisms do not influence plasma rifampicin concentrations in a South Indian population. Int J Tubercul Lung Dis. 2016;20(9):1231-5.

Pasanen MK, Neuvonen PJ, Niemi M. Global analysis of genetic variation in SLCO1B1. 2008;

Consortium HP-AS. Mapping human genetic diversity in Asia. Science. 2009;326(5959):1541-5.

Sortica VdA, Ojopi EB, Genro JP, et al. Influence of genomic ancestry on the distribution of SLCO1B1, SLCO1B3 and ABCB1 gene polymorphisms among Brazilians. Basic Clin Pharmacol Toxicol. 2012;110(5):460-8.

Sampurno OD. Tinjauan farmakogenomik Rifampisin dalam pengobatan tuberkulosis paru. Jurnal Biotek Medisiana Indonesia. 2015;59:70.

Giacomini K, Balimane P, Cho S, et al. International transporter consortium international transporter consortium commentary on clinically important transporter polymorphisms. Clin Pharmacol Ther. 2013;94:23-6.


Full Text: PDF

Refbacks

  • There are currently no refbacks.